Can Fite Biofarma(CANF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CANF Can Fite Biofarma

Market Closed 02-20 16:00:00 EST

4.65

+0.21

+4.73%

盘后4.73

+0.08+1.72%

18:31 EST

High4.65	Low4.29	Vol31.26K
Open4.45	D1 Closing4.44	Amplitude8.11%
Mkt Cap6.09M	Tradable Cap5.76M	Total Shares1.31M
T/O140.42K	T/O Rate2.52%	Tradable Shares1.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CANF","market":"US","secType":"STK","nameCN":"Can Fite Biofarma","latestPrice":4.65,"timestamp":1771621200000,"preClose":4.44,"halted":0,"volume":31264,"hourTrading":{"tag":"盘后","latestPrice":4.73,"preClose":4.65,"latestTime":"18:31 EST","volume":480,"amount":2262.65,"timestamp":1771630266411,"change":0.08,"changeRate":0.017204,"amplitude":0.017204},"delay":0,"changeRate":0.047297297297297286,"floatShares":1238800,"shares":1309212,"eps":-2665.284,"marketStatus":"Market Closed","change":0.21,"latestTime":"02-20 16:00:00 EST","open":4.45,"high":4.65,"low":4.29,"amount":140417.707088,"amplitude":0.081081,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2665.284,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":300,"listingDate":1384837200000,"exchange":"AMEX","adjPreClose":4.44,"postHourTrading":{"tag":"盘后","latestPrice":4.73,"preClose":4.65,"latestTime":"18:31 EST","volume":480,"amount":2262.65,"timestamp":1771630266411,"change":0.08,"changeRate":0.017204,"amplitude":0.017204},"volumeRatio":1.47488393590652},"requestUrl":"/m/hq/s/CANF","defaultTab":"news","newsList":[{"id":"2610630357","title":"Can-Fite BioPharma receives Canadian patent allowance for namodenoson","url":"https://stock-news.laohu8.com/highlight/detail?id=2610630357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610630357?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:15","pubTimestamp":1770639327,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma (CANF) announced that the Canadian Patent Office has issued a notice of allowance for Canadian Patent Application No. 3,126,002,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-receives-canadian-patent-allowance-for-namodenoson-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/can-fite-biopharma-receives-canadian-patent-allowance-for-namodenoson-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2604118867","title":"Can-Fite completes patient enrollment in Phase 2a study of Namodenoson","url":"https://stock-news.laohu8.com/highlight/detail?id=2604118867","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604118867?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:10","pubTimestamp":1768911021,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma (CANF) announced that patient enrollment has been completed in its Phase 2a pancreatic cancer clinical trial of Namodenoson. The...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/can-fite-completes-patient-enrollment-in-phase-2a-study-of-namodenoson-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/can-fite-completes-patient-enrollment-in-phase-2a-study-of-namodenoson-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CANF"],"gpt_icon":0},{"id":"2594299698","title":"Can-Fite BioPharma Surges in Premarket Trading After Securing Brazilian Patent for Sexual Dysfunction Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2594299698","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594299698?lang=en_us&edition=fundamental","pubTime":"2025-12-26 21:05","pubTimestamp":1766754305,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma, an Israel-based biotech company, surged in  premarket trading Friday after receiving a patent from the Brazilian Patent Office for its A3 adenosine receptor, or A3AR, drugs to treat sexual dysfunction.Sexual dysfunction can be linked to blood flow, inflammation, and metabolic issues. Can-Fite's research showed that activating the A3 adenosine receptor may affect key body signals that control sexual function, supporting the use of this treatment.The company said the patent could pave the way for partnerships or sales opportunities in Latin America. Can-Fite is also developing its A3AR drugs for cancer, inflammatory diseases, and other conditions.Shares of Can-Fite jumped more than 50% in recent pre-market trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2593533446","title":"Can-Fite BioPharma Initiating a 1-for-3,000 Reverse Share Split; ADSs Tumble","url":"https://stock-news.laohu8.com/highlight/detail?id=2593533446","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593533446?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:30","pubTimestamp":1766529000,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma's American depositary shares slid after its board of directors approved a 1-for-3,000 reverse share split.The ADSs were down 29% to 17 cents each in post-market trading on Tuesday. The ADSs retreated in the regular trading session 1.7% to close at 24 cents after touching a 52-week low earlier in the day. Year to date, the ADSs have declined 85%.Concurrently with the reverse split, Can-Fite will change the ratio of ordinary shares underlying its ADSs, from one ADS representing 300 ordinary shares to one ADS representing two ordinary shares. For holders of the company's ADSs, the ratio change will have the same effect as a 1-for-20 ADS split, according to Can-Fite. No adjustment will be made to the outstanding number of the company's ADSs, Can-Fite added.The company's shares will begin trading on a reverse stock split adjusted basis on Jan. 5.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Can-Fite BioPharma Initiating a 1-for-3,000 Reverse Share Split; ADSs Tumble","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2592970779","title":"Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2592970779","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592970779?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:51","pubTimestamp":1765975860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CANF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 07:51 ET (12:51 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2584968160","title":"Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584968160","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584968160?lang=en_us&edition=fundamental","pubTime":"2025-11-19 03:40","pubTimestamp":1763494800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CANF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 14:40 ET (19:40 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2580738027","title":"Can-Fite Biopharma Coverage Assumed by HC Wainwright & Co. at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2580738027","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580738027?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:50","pubTimestamp":1762257000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CANF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2025 06:50 ET (11:50 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2578621851","title":"Can-Fite BioPharma’s Promising Phase 2 Study on Namodenoson for Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2578621851","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578621851?lang=en_us&edition=fundamental","pubTime":"2025-10-28 01:13","pubTimestamp":1761585200,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma Ltd (($CANF)) announced an update on their ongoing clinical study. Can-Fite BioPharma Ltd (CANF) is conducting a Phase 2 clinica...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/can-fite-biopharmas-promising-phase-2-study-on-namodenoson-for-pancreatic-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/can-fite-biopharmas-promising-phase-2-study-on-namodenoson-for-pancreatic-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2567101275","title":"Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2567101275","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567101275?lang=en_us&edition=fundamental","pubTime":"2025-09-16 19:14","pubTimestamp":1758021240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CANF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 16, 2025 07:14 ET (11:14 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANF","BK4139"],"gpt_icon":0},{"id":"2564801170","title":"Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2564801170","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564801170?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:36","pubTimestamp":1756812960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CANF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 02, 2025 07:36 ET (11:36 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANF"],"gpt_icon":0},{"id":"2562037510","title":"Press Release: Can-Fite Reports H1 2025 Financial Results and Clinical Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2562037510","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562037510?lang=en_us&edition=fundamental","pubTime":"2025-08-28 20:47","pubTimestamp":1756385220,"startTime":"0","endTime":"0","summary":"Ramat Gan, Israel, Aug. 28, 2025  -- Can-Fite BioPharma Ltd.  , a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced financial results and clinical updates for H1, 2025.Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone. The Phase 2a study  is a multicenter, open-label trial enrolling patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one line of prior therapy. The study is evaluating the safety , clinical activity, and pharmacokinetics  of Namodenoson in this patient population. Participants receive oral Namodenoson at a dose of 25 mg, administered twice daily in continuous 28-day cycles. Patients are regularly monitored for safety, and to date, Namodenoson has demonstrated a favorable safety profile. The study is led by Prof. Salomon Stemmer, a renowned oncologist and key opinion leader at the Davi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANF","BK4218","BK4139","BK4181","PK"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.canfite.com","stockEarnings":[{"period":"1week","weight":0.0265},{"period":"1month","weight":0.1397},{"period":"3month","weight":-0.2038},{"period":"6month","weight":-0.6483},{"period":"1year","weight":-0.8783},{"period":"ytd","weight":0.1625}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.230769,"avgChangeRate":-0.076322},{"month":2,"riseRate":0.615385,"avgChangeRate":0.006609},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.067966},{"month":4,"riseRate":0.25,"avgChangeRate":-0.06706},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.022087},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.014382},{"month":7,"riseRate":0.25,"avgChangeRate":-0.033089},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.032507},{"month":9,"riseRate":0.333333,"avgChangeRate":0.032332},{"month":10,"riseRate":0.25,"avgChangeRate":-0.068864},{"month":11,"riseRate":0.583333,"avgChangeRate":0.063516},{"month":12,"riseRate":0.230769,"avgChangeRate":-0.10464}],"exchange":"AMEX","name":"Can Fite Biofarma","nameEN":"Can Fite Biofarma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Can Fite Biofarma(CANF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Can Fite Biofarma(CANF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Can Fite Biofarma,CANF,Can Fite Biofarma股票,Can Fite Biofarma股票老虎,Can Fite Biofarma股票老虎国际,Can Fite Biofarma行情,Can Fite Biofarma股票行情,Can Fite Biofarma股价,Can Fite Biofarma股市,Can Fite Biofarma股票价格,Can Fite Biofarma股票交易,Can Fite Biofarma股票购买,Can Fite Biofarma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Can Fite Biofarma(CANF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Can Fite Biofarma(CANF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}